Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 502 Results

Page 13 of 51« First «...11 121314 15...20 30 40...»Last »

February 21, 2023

DBV Technologies to Participate in Upcoming AAAAI 2023 Congress

February 10, 2023

DBV Technologies to Participate in Upcoming Investor Conference

January 23, 2023

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

December 23, 2022

DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial

November 22, 2022

DBV Technologies to Participate in Upcoming Investor Conference

November 14, 2022

EPITOPE Study Results: Phase 3, Randomized, Double-blind, Placebo-controlled Study of Epicutaneous Immunotherapy in Peanut-allergic Toddlers

November 14, 2022

REDUCTION IN REACTION SEVERITY FOLLOWING 12 MONTHS OF EPICUTANEOUS IMMUNOTHERAPY WITH PEANUT PATCH IN TODDLERS

November 9, 2022

DBV Technologies to Highlight New Clinical Data at ACAAI 2022

November 3, 2022

DBV Technologies Reports Third Quarter Financial Results and Business Update

October 31, 2022

DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update

Page 13 of 51« First «...11 121314 15...20 30 40...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Cookies Policy

Scroll to Top